Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial

Journal of the American College of Cardiology

Volumn 49, Issue 23, 2007, Pages 2238-2246

  Gibson, C Michael ^a   Murphy, Sabina A ^a   Montalescot, Gilles ^b   Morrow, David A ^c   Ardissino, Diego ^d   Cohen, Marc ^e   Gulba, Dietrich C ^f   Kracoff, Oscar H ^g   Lewis, Basil S ^h   Roguin, Nathan ⁱ   Antman, Elliott M ^c   Braunwald, Eugene ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^f Krankenhaus Duren gem GmbH   (Germany)

^g KAPLAN MEDICAL CENTER   (Israel)

^h CARMEL MEDICAL CENTER   (Israel)

ⁱ Nahariya Hospital Israel   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; STATINE DERIVATIVE; STREPTOKINASE;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; FEMALE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249824588     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.01.093     Document Type: Article

References (17)

1. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
2. TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. JAMA 260 (1988) 2849-2858
3. Simoons M.L., Arnold A.E., Betriu A., et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1 (1988) 197-203
4. Topol E.J., Califf R.M., George B.S., et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 317 (1987) 581-588
5. Gibson C.M., Karha J., Murphy S.A., et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 42 (2003) 7-16
6. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005) 1224-1232
7. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-segment elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
8. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-segment elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149 (2005) 217-226
9. Antman E.M. The search for replacements for unfractionated heparin. Circulation 103 (2001) 2310-2314
10. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
11. Freedman J.E. Molecular regulation of platelet-dependent thrombosis. Circulation 112 (2005) 2725-2734
12. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs. unfractionated heparin in high-risk patients with nonST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
13. Cohen M., Mahaffey K.W., Pieper K., et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 48 (2006) 1346-1354
14. Borentain M., Montalescot G., Bouzamondo A., Choussat R., Hulot J.S., and Lechat P. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter Cardiovasc Interv 65 (2005) 212-221
15. Montalescot G., White H.D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355 (2006) 1006-1017
16. MICHELANGELO OASIS-5 Steering Committee. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with nonST-segment elevation acute coronary syndromes. Am Heart J 150 (2005) 1107
17. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530